NEW YORK and LONDON, Nov. 28, 2017 /PRNewswire/ -- MeiraGTx, a New York and Londonbased gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will present an overview of the company and its clinical programs at the Barclays Gene Editing & Gene
About MeiraGTx MeiraGTx is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. The company is developing treatments for ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD). MeiraGTx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers, as well as certain neurodegenerative diseases. In addition, MeiraGTx is developing novel gene regulation platforms that promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
Contact:Andy MerrillProsek Partners212-279-3115, ext. 216
View original content:http://www.prnewswire.com/news-releases/meiragtx-to-present-at-barclays-gene-editing--gene-therapy-summit-300562308.html
Subscribe to our Free Newsletters!
Bladder neck incision is a surgical procedure where cuts are made in the neck of the urinary ...
Tourette syndrome (TS) is a neurological disorder wherein the affected person makes repetitive and ...
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...View All